Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial

BACKGROUND: Immune checkpoint inhibitors (ICIs) to date have demonstrated limited activity in advanced ovarian cancer (OC). Folate receptor alpha (FRα) is overexpressed in the majority of OCs and presents an attractive target for a combination immunotherapy to potentially overcome resistance to ICI...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamarin, Dmitriy, Walderich, Sven, Holland, Aliya, Zhou, Qin, Iasonos, Alexia E, Torrisi, Jean M, Merghoub, Taha, Chesebrough, Lewis F, Mcdonnell, Autumn S, Gallagher, Jacqueline M, Li, Yanyun, Hollmann, Travis J, Grisham, Rachel N, Erskine, Courtney L, Block, Mathew S, Knutson, Keith L, O’Cearbhaill, Roisin E, Aghajanian, Carol, Konner, Jason A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical Trials Monitor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279674/
https://www.ncbi.nlm.nih.gov/pubmed/32503949
http://dx.doi.org/10.1136/jitc-2020-000829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279674/
https://www.ncbi.nlm.nih.gov/pubmed/32503949
http://dx.doi.org/10.1136/jitc-2020-000829

Ejemplares similares